Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Important Progress in the Fight against Testicular Cancer

25.03.2019

Researchers at the University of Bremen have made great progress in the fight against testicular cancer. An important biomarker has been developed further in a comprehensive study and is almost ready for clinical application. The results have now been published in a prestigious scientific journal.

Testicular cancer is the most common malignant tumor in young men between 20 and 40 years of age. Determining the concentration of so-called biomarkers in patients’ blood is an important tool for assessing the course of the disease – but for a long time doctors lacked reliable biomarkers.


Successful in the further development of a biomarker for testicular cancer detection: Dr. Arlo Radtke (left) and PD Dr. Ganzafer Belge from the Faculty of Biology at the University of Bremen

Kai Uwe Bohn / University of Bremen


Successful in the further development of a biomarker for testicular cancer detection: PD Dr. Ganzafer Belge (left) and Dr. Arlo Radtke from the Faculty of Biology at the University of Bremen

Kai Uwe Bohn / University of Bremen

A first important step forward was therefore the discovery of an extremely promising biomarker in 2012. A working group led by human geneticist Dr. Gazanfer Belge from the University of Bremen demonstrated the effectiveness of this marker in eleven patients with testicular cancer.

37 European Clinics Involved

Even though a first step has been made in medical research, many more generally have to follow before an important discovery one day ends up in clinical routine. “No doctor in the world will rely on biomarkers that have been tested on only a dozen patients,” says Belge.

The startling discovery seven years ago prompted the Wilhelm Sander-Stiftung für Krebsforschung (foundation for cancer research) to set up a follow-up project funded with 170,000 euros. The third-party funding enabled a multiyear, multicenter study in which 37 urology and oncology clinics in various European countries participated.

“Over the past three years, the biomarker has been tested on more than 600 patients and has undergone considerable further development,” said the human geneticist.

The result was that the biomarker, which was researched and developed at the University of Bremen, is now extremely sensitive and therefore highly accurate. “After testicular cancer treatment with chemotherapy or radiation, success is checked with the help of imaging procedures and blood tests.

The biomarker we developed correctly indicates, in 94% of healthy cases, that the patients treated are actually negative for germ cell tumors,” explains Dr. Arlo Radtke, who conducted the study together with Gazanfer Belge. “For the medical sector, this means a very good detection rate. The study has shown that the biomarker is a safe tool for both initial diagnosis and post-treatment monitoring.”

183,000 Euros for Follow-Up Study

On the clinical side, Professor Klaus-Peter Dieckmann from the Asklepios Hodentumorzentrum West (testicular tumor center) in Hamburg-Altona was one of the most important medical experts involved. He confirms the high efficacy of the biomarker named miR-371-3p: “From a practitioner’s point of view, the new tumor marker is an important tool in the aftercare of testicular cancer patients.”

Due to the renewed positive results, the Deutsche Krebshilfe foundation has decided to finance another follow-up study with 183,000 euros. The project will run for two years and aims to clinically establish the biomarker for the aftercare of testicular tumor patients.

Dr. Arlo Radtke will also be involved in the important step from feasibility in the laboratory to creating a marketable product ready for application. After completing the study, which was financed by the Wilhelm Sander-Stiftung, he joined the team of the young start-up miRdetect GmbH, which plans to market the new serous tumor marker for testicular cancer.

The company was founded with the help of existing federal funding by the former Bremen university researchers Meike Spiekermann and Nina Winter. Both had worked together with Gazanfer Belge until 2015.

Publication in Prestigious Scientific Journal

The results of the Bremen study have attracted a great deal of attention among experts and have now been published in the Journal of Clinical Oncology. With an impact factor of 26.3, the publication is one of the most important scientific journals in the world. The number reflects the influence of a scientific journal and shows how often the articles of a particular journal are cited in other publications.

Additional Information:

Article in the Journal of Clinical Oncology: http://ascopubs.org/doi/abs/10.1200/JCO.18.01480
www.uni-bremen.de

Contact:

PD Dr. Gazanfer Belge
University of Bremen
Department of Biology/Chemistry
Tel.: +49 421 218-61570
E-mail: belge@uni-bremen.de

Wissenschaftliche Ansprechpartner:

PD Dr. Gazanfer Belge
University of Bremen
Department of Biology/Chemistry
Tel.: +49 421 218-61570
E-mail: belge@uni-bremen.de

Originalpublikation:

http://ascopubs.org/doi/abs/10.1200/JCO.18.01480

Kai Uwe Bohn | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Tracing the evolution of vision
23.08.2019 | University of Göttingen

nachricht Caffeine does not influence stingless bees
23.08.2019 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Hamburg and Kiel researchers observe spontaneous occurrence of skyrmions in atomically thin cobalt films

Since their experimental discovery, magnetic skyrmions - tiny magnetic knots - have moved into the focus of research. Scientists from Hamburg and Kiel have now been able to show that individual magnetic skyrmions with a diameter of only a few nanometres can be stabilised in magnetic metal films even without an external magnetic field. They report on their discovery in the journal Nature Communications.

The existence of magnetic skyrmions as particle-like objects was predicted 30 years ago by theoretical physicists, but could only be proven experimentally in...

Im Focus: Physicists create world's smallest engine

Theoretical physicists at Trinity College Dublin are among an international collaboration that has built the world's smallest engine - which, as a single calcium ion, is approximately ten billion times smaller than a car engine.

Work performed by Professor John Goold's QuSys group in Trinity's School of Physics describes the science behind this tiny motor.

Im Focus: Quantum computers to become portable

Together with the University of Innsbruck, the ETH Zurich and Interactive Fully Electrical Vehicles SRL, Infineon Austria is researching specific questions on the commercial use of quantum computers. With new innovations in design and manufacturing, the partners from universities and industry want to develop affordable components for quantum computers.

Ion traps have proven to be a very successful technology for the control and manipulation of quantum particles. Today, they form the heart of the first...

Im Focus: Towards an 'orrery' for quantum gauge theory

Experimental progress towards engineering quantized gauge fields coupled to ultracold matter promises a versatile platform to tackle problems ranging from condensed-matter to high-energy physics

The interaction between fields and matter is a recurring theme throughout physics. Classical cases such as the trajectories of one celestial body moving in the...

Im Focus: A miniature stretchable pump for the next generation of soft robots

Soft robots have a distinct advantage over their rigid forebears: they can adapt to complex environments, handle fragile objects and interact safely with humans. Made from silicone, rubber or other stretchable polymers, they are ideal for use in rehabilitation exoskeletons and robotic clothing. Soft bio-inspired robots could one day be deployed to explore remote or dangerous environments.

Most soft robots are actuated by rigid, noisy pumps that push fluids into the machines' moving parts. Because they are connected to these bulky pumps by tubes,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

The power of thought – the key to success: CYBATHLON BCI Series 2019

16.08.2019 | Event News

4th Hybrid Materials and Structures 2020 28 - 29 April 2020, Karlsruhe, Germany

14.08.2019 | Event News

What will the digital city of the future look like? City Science Summit on 1st and 2nd October 2019 in Hamburg

12.08.2019 | Event News

 
Latest News

Making small intestine endoscopy faster with a pill-sized high-tech camera

23.08.2019 | Medical Engineering

More reliable operation offshore wind farms

23.08.2019 | Power and Electrical Engineering

Tracing the evolution of vision

23.08.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>